Frédéric A. Houssiau, MD, PhD
Quick facts
Phase 3 pipeline
- RTX infusions · Immunology
RTX (rituximab) is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen on their surface.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Frédéric A. Houssiau, MD, PhD
What is Frédéric A. Houssiau, MD, PhD's pipeline?
Frédéric A. Houssiau, MD, PhD has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include RTX infusions.
Related
- Sector hub: All tracked pharma companies